Innate Pharma assumed with a Buy at BTIG

BTIG assumed coverage of Innate Pharma (IPHA) with a Buy rating and $8 price target ahead of what the firm called a “crucial catalyst stretch.” BTIG noted that Innate Pharma enters 2026 with three oncology assets with catalysts in 2026: monalizumab PACIFIC-9 topline data in the second half of 2026, IPH4502 Phase 1 dose escalation data in solid tumors is also likely in the second half of 2026, and lacutamab targeting Phase 3 initiation pending financing.